For the safety of both staff and patients, we require that our research sites are COVID-19 SMART facilities. That means they use best practices to reduce virus exposure and are dedicated to ensuring they remain open and available for the research of investigational medications.
Crohn’s Disease (CD) and Ulcerative Colitis (UC) are each a type of Inflammatory Bowel Disease (IBD).
They can be progressive health conditions, meaning that symptoms like gut pain, diarrhoea and fatigue can—if not properly managed—get worse.
CD and UC are also “autoimmune” diseases. This means the body’s immune system attacks healthy tissue—in this case, different parts of the GI tract—by mistake. Fortunately, treatments exist, but more options are needed.
People may not give much thought to clinical research, but everything from aspirin to chemotherapy has been carefully tested before being prescribed by your doctor.
Clinical trials need human volunteers, who participate under the supervision of a doctor and/or health professionals. As the trial goes on, the doctors gather more and more information about the medicine or treatment under investigation. It is only through clinical trials that we learn if medicines and treatments are both effective and safe.
Dedicated to conducting clinical trials, Synexus have been investigating the effectiveness of new medicines and treatments for more than 25 years. We have vast experience in conducting clinical research with over 180 sites around the world. Each has its own dedicated team of highly trained doctors and nurses to provide our patients with the highest level of comfort and professionalism.